Voss Capital LP Grows Holdings in Actuate Therapeutics, Inc. $ACTU

Voss Capital LP grew its holdings in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU) by 45.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,300,000 shares of the company’s stock after buying an additional 403,722 shares during the quarter. Voss Capital LP owned 5.59% of Actuate Therapeutics worth $7,956,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Wells Fargo & Company MN boosted its stake in shares of Actuate Therapeutics by 48.8% during the 4th quarter. Wells Fargo & Company MN now owns 20,146 shares of the company’s stock valued at $123,000 after buying an additional 6,604 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Actuate Therapeutics during the 4th quarter valued at approximately $102,000. Deutsche Bank AG boosted its stake in shares of Actuate Therapeutics by 640.0% during the 4th quarter. Deutsche Bank AG now owns 9,309 shares of the company’s stock valued at $57,000 after buying an additional 8,051 shares during the last quarter. Sfmg LLC boosted its stake in shares of Actuate Therapeutics by 17.6% during the 4th quarter. Sfmg LLC now owns 20,000 shares of the company’s stock valued at $122,000 after buying an additional 3,000 shares during the last quarter. Finally, Rock Creek Group LP purchased a new position in shares of Actuate Therapeutics during the 4th quarter valued at approximately $133,000.

Actuate Therapeutics Trading Up 1.5%

ACTU stock opened at $2.02 on Friday. The firm has a market cap of $48.34 million, a P/E ratio of -2.08 and a beta of 0.52. Actuate Therapeutics, Inc. has a 12-month low of $1.58 and a 12-month high of $9.22. The stock’s 50 day simple moving average is $2.38 and its 200 day simple moving average is $4.08.

Actuate Therapeutics (NASDAQ:ACTU) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.01). On average, research analysts forecast that Actuate Therapeutics, Inc. will post -0.86 EPS for the current fiscal year.

Analysts Set New Price Targets

ACTU has been the subject of several research analyst reports. HC Wainwright reiterated a “buy” rating on shares of Actuate Therapeutics in a research note on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Friday, March 27th. Finally, Wall Street Zen cut Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Actuate Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $17.50.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.